Rubius

J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board

Retrieved on: 
화요일, 2월 27, 2024

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.
  • Mr. Epstein will now advise the J.P. Morgan Life Sciences Private Capital team.
  • The J.P. Morgan Life Sciences Private Capital team leverages JPMorgan Chase's scale, resources, data assets and healthcare expertise and sits within J.P. Morgan Private Capital, a venture and growth equity investment platform that is part of J.P. Morgan Asset Management.
  • The platform finances the continued growth of private companies and taps into significant pre-IPO value creation opportunities in the consumer and technology, and life sciences sectors.

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Retrieved on: 
화요일, 2월 6, 2024

Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry.

Key Points: 
  • Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry.
  • “We are pleased to welcome Dawn to TScan at such an exciting time in the Company’s evolution,” said Debora Barton, M.D., Chief Medical Officer.
  • “Her expertise in cell and gene therapy clinical development and experience with regulatory interactions, most recently at ElevateBio, will be crucial as we advance our clinical-stage pipeline across heme malignancies and solid tumors.
  • from Drexel University College of Medicine, and an M.S., Clinical and Translational Research, from the University of Cincinnati.

The Rett Syndrome Research Trust Strengthens Research Team with Addition of Robert Deans as Chief Technology Officer

Retrieved on: 
화요일, 1월 16, 2024

TRUMBULL, Conn., Jan. 16, 2024 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is excited to announce the addition of Robert Deans, PhD, as Chief Technology Officer, Head of Research. Deans brings a wealth of genetic medicine knowledge and hands-on industry experience to RSRT. Most recently, he served as Chief Technology Officer of BlueRock Therapeutics, where he led the charge on stem cell and gene therapy approaches. Deans previously served as Chief Scientific Officer of Rubius Therapeutics and Executive Vice President at Athersys, where he advanced a number of stem cell therapeutics into late-stage clinical development.

Key Points: 
  • The Rett Syndrome Research Trust (RSRT) is excited to announce the addition of Robert Deans, PhD, as Chief Technology Officer, Head of Research.
  • Most recently, he served as Chief Technology Officer of BlueRock Therapeutics, where he led the charge on stem cell and gene therapy approaches.
  • TRUMBULL, Conn., Jan. 16, 2024 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is excited to announce the addition of Robert Deans, PhD, as Chief Technology Officer, Head of Research.
  • Deans' colleagues include Randall Carpenter, MD, Chief Medical Officer; Jana von Hehn, PhD, Chief Scientific Officer, Head of Clinical Development; and Monica Coenraads, Chief Executive Officer.

Entrada Therapeutics Promotes Nathan J. Dowden to President

Retrieved on: 
수요일, 1월 3, 2024

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that Nathan J. Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024.

Key Points: 
  • “Nate has played an important role in helping to guide Entrada’s growth and has contributed to the building of an inspired team with the potential to make a difference for patients,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics.
  • “His strategic and operational expertise in the life science sector has helped advance our ENTR-601-44 program into the clinic, build our diverse pipeline of intracellular therapeutics, and establish our new headquarters in the Boston Seaport.
  • Prior to Entrada, Nate served as Senior Vice President of Corporate Development at Rubius Therapeutics, where he supported the organization’s evolution from an early-stage discovery company into a clinical development organization.
  • “It has been a pleasure contributing to Entrada’s mission to treat devastating diseases with intracellular therapeutics and I am privileged to help continue to support the Company in my new role as President and Chief Operating Officer.”

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Retrieved on: 
수요일, 11월 15, 2023

DUBLIN, Ireland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) today launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Mural’s ordinary shares will begin trading on the Nasdaq Global Market tomorrow, November 16th, under the ticker symbol “MURA”.

Key Points: 
  • “Immunotherapies have made a tremendous impact on the treatment of cancers over the past decade,” said Caroline Loew, Ph.D., the Company’s chief executive officer.
  • We believe Mural Oncology can lead the future of immunotherapies for patients.
  • Our protein engineering expertise allows us to reimagine the development of pro-inflammatory cytokine-based therapeutics that could address the key limitations with current cancer immunotherapies.
  • Goodwin Procter LLP and Arthur Cox LLP are serving as legal counsel to Mural Oncology.

AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases

Retrieved on: 
화요일, 9월 19, 2023

AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today emerged from stealth with a $30 million initial financing led by ARCH Venture Partners.

Key Points: 
  • AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today emerged from stealth with a $30 million initial financing led by ARCH Venture Partners.
  • The financing enables AIRNA’s experienced team to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+TM.
  • “RNA editing is poised to lead the next generation of RNA therapeutics by targeting diseases not accessible through other approaches with a medicine that can be delivered to large patient populations,” said Kris Elverum, President and CEO of AIRNA.
  • “After making several technological improvements, I’m excited to see AIRNA advancing RNA editing therapeutics into precise medicines that could really impact patient’s lives.”
    RNA editing is a disruptive therapeutic modality with unique potential to unlock the full promise of genetically defined medicines for rare and common diseases.

COUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer

Retrieved on: 
수요일, 7월 19, 2023

CHICAGO, July 19, 2023 /PRNewswire/ -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system, today announced the appointment of Dannielle Appelhans as Chief Operating Officer, effective immediately.

Key Points: 
  • CHICAGO, July 19, 2023 /PRNewswire/ -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system, today announced the appointment of Dannielle Appelhans as Chief Operating Officer, effective immediately.
  • Ms. Appelhans served most recently as the Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded and clinical-phase biopharmaceutical company pioneering cellular medicines.
  • She previously served as its Chief Operating Officer, where she oversaw corporate strategy, communications, quality, technical development, and operations.
  • "COUR represents an ideal opportunity to apply my relevant skill-set at an important inflection point in the Company's evolution in bringing two promising, proprietary autoimmune programs to treat Myasthenia Gravis and type 1 diabetes into human proof-of-concept studies in the near-term," said Dannielle Appelhans, incoming Chief Operating Officer at COUR Pharmaceuticals.

Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

Retrieved on: 
월요일, 5월 8, 2023

Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D.
  • President and Head of Research & Development (R&D) effective June 5, 2023.
  • “This newly created role integrates chemistry, biology and development with the goal of maximizing the impact of our portfolio and accelerating our innovative pipeline,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • “Incyte has a strong foundation of bringing first-in-class treatments to patients and I am honored to join the organization,” said Dr. Cagnoni.

Modular Devices Acquisition, LLC Welcomes Chris Patterson as Vice President of Cleanrooms Division

Retrieved on: 
월요일, 3월 13, 2023

Modular Devices Acquisition, LLC (Modular Devices), a renowned provider of mobile cath labs and mobile cleanrooms, is proud to announce the appointment of Chris Patterson as the Vice President of the Cleanrooms division.

Key Points: 
  • Modular Devices Acquisition, LLC (Modular Devices), a renowned provider of mobile cath labs and mobile cleanrooms, is proud to announce the appointment of Chris Patterson as the Vice President of the Cleanrooms division.
  • View the full release here: https://www.businesswire.com/news/home/20230313005415/en/
    Chris Patterson, Vice President - Cleanrooms (Photo: Business Wire)
    Patterson brings extensive experience to his new role, with a background in facilities, engineering, operations, and project management.
  • At Modular Devices, Patterson will lead the Cleanrooms division, focusing on expanding into the Life Sciences market, building the cleanrooms business, and contributing to the overall success of Modular Devices.
  • Chief Revenue Officer (CRO) Mark Koers said, “We’re delighted to welcome such an experienced cleanrooms engineer as the new VP of Cleanrooms for Modular Devices.

Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

Retrieved on: 
화요일, 2월 28, 2023

MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel.

Key Points: 
  • MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel.
  • Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight.
  • “We are excited to welcome Jennifer to our leadership team,” said Brian McKelligon, Chief Executive Officer of Akoya.
  • Prior to joining Rubius, she was Associate General Counsel for Progress Software Corporation where she oversaw the company’s corporate, securities law, and mergers and acquisitions activities.